First Author: R.Rothwell PORTUGAL
Co Author(s): S. Fonseca L. Ribeiro L. Silva M. Queirós A. Brandão L. Agrelos 0 0 0 0 0 0 0 0 0
Back to previous
To compare ranibizumab and bevacizumab in the treatment of macular edema (ME) subsequent to retinal vein occlusion (RVO).
Gaia Hospital, Portugal
A comparative, retrospective, non randomized study of 22 eyes of 22 patients with RVO and ME that were treated with on demand intravitreous injections of 0.5mg ranibizumab (n=12) and 1.25mg of bevacizumab (n=10) during a 6 month follow up period. The two main outcomes were the best corrected visual acuity (BCVA) and the reduction of central foveal thickness (CFT) at month 6.
In both groups there was an improvement in BCVA in months 1, 3 and 6 with no statistically significant difference between groups. In month 6 there was an improvement of 0.20 in the ranibizumab group and of 0.19 in the bevacizumab group in the Snellen decimal scale (p>0.05). The BCVA was ≥0,5 in 25% of patients in the ranibizumab group and in 20% of the bevacizumab group (p>0.05). The reduction of the CFT was 320.67μm in the ranibizumab group and 322.80μm in the bevacizumab group (p>0.05), without a statistically significant difference between groups. Retinal tears, retinal detachments or endophthalmitis did not occur after treatments. There were no systemic complications.
In patients with ME secondary to RVO, treatment with bevacizumab and ranibizumab appears to be equally safe and effective. Multicentric randomized studies are necessary to corroborate our results.